Clinical Implications of Low Parathyroid Hormone in Dialysis Patients

Definition and Diagnostic Thresholds

PTH levels below 150 pg/mL in dialysis patients denote relative hypoparathyroidism and are linked to adynamic bone disease. 1
PTH values under 100 pg/mL should raise concern for development of adynamic bone disease. 2

Low PTH reflects adynamic bone disease, a state of markedly reduced bone turnover that eliminates the skeleton’s normal role in calcium and phosphate homeostasis. 3
Inadynamic bone cannot adequately buffer calcium or phosphate, resulting in a four‑fold higher risk of hip fracture compared with the general population; additional risk is conferred by older age, longer dialysis vintage, female sex, and diabetes. 3
Reduced bone density together with low PTH increases the incidence of vertebral collapse fractures. 3
Minimal calcium loading can produce pronounced hypercalcemia because the bone fails to sequester calcium. 3
Impaired skeletal calcium incorporation predisposes to metastatic calcification in soft tissues. 3
Calciphylaxis cases have been associated with low PTH levels and adynamic bone histology. 3

Hypercalcemia from any source suppresses parathyroid hormone secretion. 1
Elevated vitamin D levels, whether iatrogenic or endogenous, contribute to PTH suppression. 1
Diabetes mellitus independently correlates with lower PTH concentrations. 1
Advancing age is associated with progressively lower PTH values. 1

For patients with PTH < 150 pg/mL, lowering dialysate calcium to 1.0–2.0 mEq/L stimulates PTH secretion and promotes bone turnover. [2][3]
Targeting a PTH rise to at least 100 pg/mL helps avoid low‑turnover bone disease. 2
If PTH exceeds 300 pg/mL, dialysate calcium should be increased to prevent overt high‑turnover bone disease. 2
Prolonged use of very low dialysate calcium (1.0–1.5 mEq/L) can cause marked bone demineralization and should be avoided. 2

Decrease or discontinue calcium‑based phosphate binders to reduce excess calcium load and allow PTH recovery. 3
Reduce or stop vitamin D sterols in the setting of adynamic bone disease. 3

Maintaining PTH within the normal population range (< 65 pg/mL) in dialysis patients is inappropriate and precipitates adynamic bone disease. 4
Stage‑specific PTH targets (approximately 150–300 pg/mL for Stage 5 CKD on dialysis) should be employed rather than aiming for “normal” values. 4

The National Kidney Foundation recommends that for patients with CKD Stage 5 on dialysis, intact PTH levels should be maintained between 150-300 pg/mL to balance the risks of high-turnover and low-turnover bone disease 5, 6
PTH levels above 300 pg/mL in dialysis patients indicate high-turnover bone disease with a sensitivity of 93% and specificity of 77% 7, 8
For non-dialysis CKD patients, PTH targets should be progressively higher as kidney function declines 9

Intact PTH assays using a threshold of 150-200 pg/mL can detect high-turnover bone disorders with 93% sensitivity and 77% specificity 8
Low-turnover bone disorders can be diagnosed using a PTH threshold of 60 pg/mL with 70% sensitivity and 87% specificity 8
Current guidelines recommend a wide target range to minimize the risk of developing adynamic bone disease while preventing severe hyperparathyroidism 9

For patients on dialysis initiating vitamin D sterol therapy, PTH should be measured monthly for at least 3 months and then every 3 months once target levels are achieved 5
PTH measurements should be interpreted as trends rather than isolated values due to assay variability and biological fluctuations 9
Monitoring should begin when GFR falls below 60 mL/min/1.73 m² (CKD Stage 3) 10

When PTH levels exceed 300 pg/mL in dialysis patients, active vitamin D sterols should be initiated to reduce PTH to the target range 5
Intermittent intravenous administration of calcitriol is more effective than daily oral calcitriol in lowering serum PTH levels 5
Treatment decisions should consider calcium and phosphorus levels alongside PTH, as hypercalcemia or hyperphosphatemia may necessitate adjustments in therapy 5

Newer assays specific for 1-84 PTH may provide more accurate assessment of biologically active PTH but are not yet standard clinical tools 8
Relying solely on PTH without considering calcium and phosphorus levels can lead to suboptimal management of CKD-MBD 9